{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"105"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"description":"Safety was defined as the number of participants with treatment emergent adverse events, including laboratory abnormalities, ECG changes, and/or physical examination findings.","groups":[{"description":"Tebentafusp administered at 20 mcg at Cycle 1 Day 1, 30 mcg at Cycle 1 Day 8, and 68 mcg at Cycle 1 Day 15 by IV infusion and weekly thereafter.","id":"OG000","title":"Tebentafusp"},{"description":"1 of 3 Investigator's Choice options: Systemic Dacarbazine, Ipilimumab or Pembrolizumab. Dacarbazine: administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity; Ipilimumab: administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments; Pembrolizumab: administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity.","id":"OG001","title":"Investigator's Choice"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Analysis Set includes all randomized participants who received at least 1 full or partial dose of tebentafusp or investigator's choice. Combining participants into a single group as part of the Investigator's Choice arm was pre-specified as part of the study design; therefore, data per different treatments were not analyzed.","reportingStatus":"POSTED","timeFrame":"Safety was assessed from informed consent through 90 days after end of treatment, up to 36 months.","title":"Safety: Number of Participants With Treatment Emergent Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}